The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies
Open accessAbstract
Objectives: Antimicrobial drug resistance is spreading among Enterobacteriaceae, limiting the utility of traditionally used agents. We sought to systematically review the microbiological activity and clinical effectiveness of tigecycline for multidrug-resistant (MDR) Enterobacteriaceae, including those resistant to broad-spectrum β-lactams due to the expression of extended-spectrum β-lactamases (ESBLs), AmpC enzymes and carbapenemases (including metallo-β-lactamases). Methods: PubMed was searched for articles including relevant data. Results: Twenty-six microbiological and 10 clinical studies were identified. Tigecycline was active against more than 99% of 1936 Escherichia coli isolates characterized by any of the above resistance patterns (including 1636 ESBL-producing isolates) using the US Food and Drug Administration (FDA) breakpoint of susceptibility (MIC ≤ 2 mg/L). Findings were not different using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint (≤1 mg/L). Susceptibility rates for Klebsiella spp. with any of the above resistance patterns were 91.2% for 2627 isolates by the FDA criteria and 72.3% for 1504 isolates by the EUCAST criteria (92.3% for 2030 and 72.3% for 1284 ESBL-producing isolates, by the FDA and EUCAST criteria, respectively). The degree of microbiological activity of tigecycline against 576 MDR Enterobacter spp. isolates was moderate. In clinical studies, 69.7% of the 33 reported patients treated with tigecycline achieved resolution of an infection caused by a carbapenem-resistant or ESBL-producing or MDR Enterobacteriaceae. Conclusions: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. isolates. Further evaluation of its clinical utility against such resistant Enterobacteriaceae, particularly regarding non-labelled indications, is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Visalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165
Cited by
Microbiota regulates immune defense against respiratory tract influenza A virus infection
Ichinohe, T., Pang, I. K., Kumamoto, Y., Peaper, D. R., Ho, J. H., Murray, T. S., & Iwasaki, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019378108 · Cited by 1,502
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Self-citationExtended-spectrum β-lactamase-producing organisms
Falagas, M. E., & Karageorgopoulos, D. E. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.02.021 · Cited by 346
Self-citationHawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Metadata
- Authors
- Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., & Falagas, M. E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-08-01
- Volume
- 62
- Issue
- 5
- Pages
- 895-904
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2154233284
- Cited by
- 186
- References
- 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. https://app.cochat.ai/papers/10.1093/jac/dkn311
- The paper
- Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., & Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkn311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.